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ABSTRACT 
PURPOSE: Myofascial pain syndrome is a condition which is indicated by the presence of 
myofascial trigger points in the muscle and in its fascia. It is a common cause of discomfort 
and disability worldwide. These myofascial trigger points may refer pain to various areas in 
the body. One such muscle is the glute medius muscle which refers pain into the lower back 
and which may easily be misdiagnosed as non-specific low back pain. Various soft tissue 
therapies and modalities have been used to treat myofascial trigger points in order to relieve 
local muscle tightness and the associated referred pain. The aim of this comparative study 
was to compare activator trigger point therapy with shockwave therapy in the treatment of 
glute medius trigger points. The findings were compared in terms of changes in the intensity 
and characteristics of the pain as well as pain pressure threshold measurements in order to 
highlight the treatment protocol which was the most effective in treating the glute medius 
trigger points. 
METHOD: Thirty male and female participants between the ages of 18 and 50 presenting 
with an active glute medius trigger point were randomly and equally divided into two groups. 
Each participant met both the inclusion and exclusion criteria for the study. The two groups 
each comprised of 15 participants. Group 1 received activator trigger point therapy while 
group 2 received shockwave therapy to the glute medius trigger point identified.  
PROCEDURE: Each participant who had met the criteria received six treatments over a 
three-week period with a seventh visit for the purpose of measurements only. Subjective and 
objective data was collected on visits 1, 4 and 7. The subjective data measurements included 
the numerical pain rating scale and the McGill pain questionnaire, while the objective data 
measurements were recorded by means of a pressure pain algometer.  
RESULTS: Statistical analyses was performed using non-parametric testing that included 
the Shapiro-Wilk test to test for normality. For the intra-group analysis, the Friedman and 
Wilcoxon signed rank test was conducted in order to check statistically significant changes 
between the two time periods while, for the inter-group analysis, the Mann-Whitney tests 
was performed in order to check statistically significant changes between the two groups.  
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The analyses conducted showed that the numerical pain rating scale and the McGill Pain 
Questionnaire data produced statistically and clinically significant results for both groups. 
The pressure algometer data showed statistically and/or clinically significant results in terms 
of decreasing the pain pressure threshold. The intergroup analysis of both groups showed 
no statistically significant results in respect of either the subjective or the objective data 
collection. 
 
CONCLUSION: The statistical findings showed neither one of the two treatment protocols 
used in this study to treat glute medius trigger points were superior to the other protocol. The 
intragroup and intergroup analyses both showed that neither of the treatments administered 
to either group 1 or group 2 were more effective than the other. It was, therefore, concluded 
that both treatment protocols may be used to effectively treat both glute medius trigger points 
and the associated non-specific low back pain. 
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CHAPTER 1: INTRODUCTION 
1.1 Introduction 
Myofascial pain syndrome (MPS) is defined as the presence of a myofascial trigger point 
(MTP) within a muscle or the muscle’s fascia. It is known as one of the most common pain 
conditions which are presented in the general population (Giamberardino, Affaitati, 
Costantini & Fabrizio, 2011). Travell and Simons (2019) define MPS as a complex of 
sensory, motor and autonomic symptoms that are caused by myofascial trigger points. 
A trigger point may be defined as a hyper-irritable painful site in a muscle that occurs in the 
form of a palpable taut band which results in a specific type of ischaemic, localised muscle 
pain and is often associated with referred pain. Trigger points have limited self-healing 
abilities and may also cause an autonomic response as well as restricting a full range of 
motion (Gleitz & Hornig, 2012).  
Myofascial trigger points may be classified into the following two groups, namely, active and 
latent depending on the referral patterns that may result either with or without palpation of 
the relevant area. Glute medius muscle trigger points may cause referral pain into the lower 
back and may be easily misdiagnosed as non-specific low back pain (Travell & Simons, 
2019).  
Various theories and treatment protocols on myofascial pain have been researched and 
implemented over the years by numerous specialists and therapists who practise 
conservative therapy. Conservative therapy may be divided into invasive therapy, such as 
the injection of medication, dry needling, acupuncture and wet cupping, and non-invasive 
therapy such as ultrasound, massage, laser and interferential current. The results from these 
therapies have shown all different evidence and efficiencies (Ramon, Gleitz, Hernandez & 
Romero, 2015).  
 
1.2 Aim of the Study 
The aim of this study was to compare activator trigger point therapy (ATT) with shockwave 
therapy (SWT) in the treatment of glute medius trigger points. The study findings in terms of 
the changes in the pain pressure algometer readings as well as the intensity and 
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characteristics of the pain experienced were compared. To establish which treatment 
protocol was the most effective in treating glute medius trigger points (TP). 
 
1.3 Possible Outcomes of the Study 
The study was intended to determine which treatment protocol, namely, activator trigger 
point therapy or shockwave therapy, was the most effective in treating glute medius trigger 
points. Results of this study perhaps contributing to the existing body of knowledge on the 
effects of trigger point therapy and improving management protocols. In addition, it was 
hoped that the study findings may provide chiropractors with an alternative, non-invasive 
form of treating glute medius trigger points, as well as additional information on the 
employment of and benefits to a patient arising from either an activator or shockwave therapy 
to treat myofascial trigger points.   
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CHAPTER 2: LITERATURE REVIEW 
 
2.1 Introduction 
This chapter presents a review of existing literature on the research topic and contains the 
theoretical content appropriate to the study. As such, the chapter contains relevant 
information on the anatomy of the glute medius muscle, myofascial trigger points as well as 
the two modalities used in the study to treat myofascial trigger points (TPs). Muscle anatomy 
is important and is related to the treatment of myofascial TPs. 
 
2.2 Skeletal Muscle 
2.2.1 Skeletal muscle structure 
Muscle tissue consist primarily of muscle cells that are highly specialised for the purposes 
of contraction. One such type of muscle tissue is skeletal muscle. Skeletal muscles are 
organs composed of skeletal muscle tissue, connective tissue, nerves and blood vessels. 
Skeletal muscles are controlled by the somatic nervous system and generate movement and 
stability around joints and surrounding structures.  
Each muscle may be divided into the following three layers of connective tissue (see figure 
2.1 below): 
(1) Epimysium: The outermost dense layer of collagen fibres, surrounds the entire 
muscle and separates the muscle from tissues and organs. 
(2) Perimysium: Divides the muscle into compartments. Each compartment contains a 
fascicle – a bundle of muscle fibres.  
(3) Endomysium: Layer of connective tissue surrounding each muscle fibre in a fascicle 
(Martini, Nath & Bartholomew, 2012). 
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Figure 2.1 Organisation of skeletal muscles (Martini, Nath & Bartholomew, 2012). 
 
2.2.2 Muscle contraction 
Muscle contractions are controlled by the sarcomere, which are the smallest functional unit 
in the muscle fibre. Sarcomeres consist of A-bands (thick filament) and an I-bands (thin 
filament) with the interaction between these two bands resulting in a muscle contraction.  
During a muscle contraction the following occurs (see figure 2.2 below): 
• I-bands and H-bands of sarcomere become smaller. 
• Zones of overlap increase. 
• Z-lines move closer. 
• Width of A-band remains normal. 
The above is known as the sliding filament theory with the thin filaments moving closer to 
the centre of the sarcomere (Martini et al., 2012). 
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Figure 2.2 Changes in the sarcomere during muscle contraction (Martini et al., 2012) 
 
2.2.3 Anatomy of the glute medius muscle 
a. Muscle attachment 
The glute medius muscle may be seen as an analogous to the deltoid muscle in the shoulder. 
It is a thick, multipennate, fan-shaped muscle in the pelvis that lies deep to the glute maximus 
muscle but superficial to glute minimus muscle (see figure 2.3) (Travell & Simons, 2019). 
The glute medius muscle attachments are presented in table 2.1. 
 
Table 2.1 Glute medius muscle attachments (Moore, Dally & Agur, 2014) 
Muscle Origin Insertion 
Glute medius External surface of ilium between 
anterior and posterior gluteal lines 
Lateral surface of greater trochanter of 
femur 
 
b. Action 
The glute medius muscle acts with the glute minimus as a strong hip abductor. Both the 
anterior and the posterior fibres of the glute medius are responsible for abduction while the 
anterior fibres on their own are capable of assisting in the internal rotation of the femur. The 
main action of the glute medius muscle is to stabilise the pelvis on the femur and to support 
the lower extremity during mid-stance of the gate cycle (Travell & Simons, 2019). 
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c. Innervation 
The glute medius muscle is innervated by the superior gluteal nerve that originates in lumbar 
nerve roots four and five as well as sacral nerve root one (L4, L5 and S1). It passes between 
both the glute medius and minimus muscle (Travell & Simons, 2019). 
 
Figure 2.3 Attachment of the right glute medius muscle in the posterolateral view 
(Travell & Simons 2019) 
 
d. Blood supply 
The glute medius muscle is supplied by the deep branch of the superior gluteal artery which 
arises from the femoral artery. The superior gluteal artery exits the pelvis through the greater 
sciatic foramen and runs with the superior gluteal nerve (Travell & Simons, 2019). 
 
2.2.4 Glute medius trigger point location and referral pattern 
a. Location 
There are three myofascial trigger points identified in the glute medius muscle, namely: (1) 
lateral iliac crest, (2) mid iliac crest and (3) posterior superior iliac spine.  
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b. Referral pattern 
As illustrated in figure 2.4, these myofascial trigger points have specific referral patterns: 
• The trigger points (TPs) near the lateral iliac crest or anterior portion of the muscle 
refer pain over the sacrum, coccyx and gluteal cleft (Vizniak, 2015). The muscle 
fibres are also more palpable in this area and may result in referred pain into the 
lower portion of the lumbar spine (Travell & Simons, 2019).  
• The TPs near the mid iliac crest or middle of the muscle refer pain over the entire 
buttock and posterior proximal thigh (Vizniak, 2015). 
• The TPs near the posterior superior iliac crest or posterior portion of the muscle refer 
pain to the gluteal cleft, gluteal fold and sacroiliac joint (Vizniak, 2015).   
 
 
Figure 2.4 Glute medius muscle trigger point locations and referral patterns (Travell 
& Simons, 2019) 
 
2.3 Myofascial Trigger Points 
2.3.1 Introduction 
Myofascial pain syndrome is described as the sensory, motor and autonomic symptoms that 
result from the myofascial trigger points. Myofascial TPs are defined as a hyperirritable band 
within the skeletal muscle and which are associated with a palpable nodule within the 
hyperirritable band. TPs are tender or painful on palpation and may result in a characteristic 
referred pain, motor dysfunction and autonomic phenomena (Sharan, Rajkumar, Mohandoss 
& Ranganathan, 2014).  
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There are two different types of myofascial TPs, namely: 1) active TPs which produce the 
characteristic local and/or referred pain at rest and which are associated with a characteristic 
referral pattern and 2) latent TPs which are seen to be in the dormant stage and produce 
symptoms only when palpated (Travell & Simons, 2019). 
 
2.3.2 Pathogenesis of myofascial trigger points 
a. Integrated hypothesis theory 
The integrated hypothesis theory refers to TP formation in an area with numerous 
dysfunctional motor endplates (Rickards, 2006). This theory may be seen as a combined 
explanation of the energy crisis theory and the motor endplate dysfunction theory.  
 
The integrated hypothesis theory cites local myofascial tissue, the central nervous system 
and biomechanical factors and may be described as an increase in the release of 
acetylcholine which results in increased muscle fibre tension and producing the taut band 
appearance in a TP. This gives rise to hypoxia as a result of the blood vessel constriction 
caused by the taut band formation. Reduced oxygen to the tissue then disrupts the 
mitochondrial energy metabolism, thus decreasing ATP (adenosine triphosphate) and 
resulting in tissue distress and the release of sensitising substances. These sensitising 
substances lead to both nociceptor activation and autonomic modulation (Jafri, 2014). 
 
2.3.3 Predisposing factors for the development of trigger points 
Factors predisposing the formation of a TP (Cummings & Baldry, 2007): 
• Decreased circulation: Reduced blood supply may result in local hypoxia in a 
muscle. 
• Nerve root compression: Compression due to either disc prolapse or spondylosis 
may lead to TP formation. 
• Visceral pain: May activate latent TP when referring to the skin surface or specific 
muscle. 
• Anxiety: Anxiousness may result in prolonged muscle contraction, thus causing 
shortened muscle for long periods. This may lead to TP formation. 
• Trauma: Muscle strain due to either macro- or micro-trauma may cause TP 
formation. 
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• Climate: Either hot or cold weather conditions may activate latent TP. 
• Ergonomics: Poor posture increases the load on muscles which result in TP 
formation.  
 
2.3.4 Clinical features and classification of myofascial trigger points 
 
Table 2.2 Active trigger points versus latent trigger points (Travell & Simons, 2019) 
Active trigger points Latent trigger points 
Produces or refers the pain described by 
the patient 
Unknown local or referred pain 
Voluntary local or referred pain Pain on palpation or when needled 
Symptoms produced by palpation are 
familiar to the patient 
Do not reproduce symptoms experienced 
by the patient 
Reproduces any symptoms, not just pain 
related symptoms 
Symptoms on palpation are not recognised 
by patient 
Symptoms may be absent at the time of 
examination but may be identified during 
palpation 
 
 
2.3.5 Diagnosis of myofascial trigger points 
A myofascial TP may be diagnosed according to five major criteria while a minimum of one 
minor criterion should also be included. 
Five major criteria (Giamberardino et al., 2011): 
• Taut band palpable within the muscle 
• Decreased range of motion 
• Pain referral pattern that causes a change in sensation 
• Local tenderness on palpation 
• Spontaneous localised pain 
Three minor criteria (Giamberardino et al., 2011): 
• Pain relief when muscle is stretched 
• Pain during palpation or needling 
• Local compression reproduces pain that the patient is experiencing 
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2.3.6 Identification of a trigger point (Dommerholt & Huijbreghts, 2010); 
Principles that may be used to effectively identify a myofascial TP. 
• Palpation of the taut band reproduces the referred pain or symptoms. 
• Flat palpation or pincer grip are two techniques that may be used to locate a taut 
band within the muscle. 
• Local tenderness on palpation over a taut band. 
• Occurrence of a local twitch response is a characteristic feature of a myofascial TP. 
 
2.4 Treatment of Myofascial Trigger Points with an Activator 
An activator is a hand-held device that may be used to deliver specific, reproducible and 
controlled forces to an identified area. It is used mainly by chiropractors as a joint fixation 
adjusting method but is also suggested for trigger point therapy as it allows a force to be 
delivered to a specific, identified point. Previous studies have shown that activator trigger 
point therapy results in decreased pain and sensitivity in the identified TP (Blikstad & 
Gemmell, 2008).  
 
Blikstad and Gemmell (2008) suggested that trigger point therapy using an activator should 
be applied in the form of 10 thrusts at a rate of one thrust per second. For the purposes of 
this study the force settings of the activator ranged from 9 to 20 kilogram-force AFR (average 
force range) and was set on a 15 kilogram-force AFR when the activator was placed 
perpendicular to the taut band identified in the TP.  
 
The concept of using the activator to treat myofascial trigger points has not yet been 
investigated despite the fact that Blikstad and Gemell (2008) hypothesised that when a 
controlled and reproducible force is delivered to a specific point, it results in the lengthening 
of the muscle fibres due to the reduction in the height of the TP. The increased length of the 
TP causes a disturbance in the sarcolemma and normalises all the sarcomeres that are 
involved, thus resulting in an overall reduction in both pain and disability and also releasing 
the muscle tension caused by the TP (Blikstad & Gemmell, 2008).  
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2.5 Treatment of Myofascial Trigger Points with Shockwave Therapy 
Extracorporeal shockwave therapy (ESWT) is a relatively new technological development 
which makes use of acoustic waves that are distinguished by both their short rapid changes 
in pressure and their high amplitude to transfer energy to tissues. The waves penetrate the 
skin non-invasively and result in a series of biological changes that result in tissue 
neovascularisation and healing (Gruenwald, Appel, Kitrey & Vardi, 2013). In the early 1970s, 
shockwave therapy was used non-invasively to treat kidney stones in patients and was 
known as lithotripsy (Watson, 2015). Researchers then noticed both the osteoblastic 
response in animal studies that was conducted in the mid-1980s and also the effect that 
ESWT had on cartilage, fascia, tendons and ligaments (Wang, 2012). In the 1990s, the 
success of ESWT in treating musculoskeletal conditions was recognised (McClure, 2004). 
ESWT have been proved to be a safe and effective treatment protocol for several 
orthopaedic related conditions such as, inter alia, lateral epicondylitis, plantar fasciitis, rotator 
cuff tendinopathy, Achilles tendinopathy and greater trochanter bursitis (Reilly, Bluman & 
Tenford, 2018). Research has also been conducted into other conditions such as avascular 
necrosis of the femoral head, non-union of long bone fractures, regional pain syndrome, 
osteoarthritis of the knee and spinal fusion (Wang, 2012). Shockwave therapy has been 
found to result in pain reduction, increased metabolism, increased blood supply and reduced 
muscle tone. In addition, it also induces the characteristic referred pain associated with the 
TP being treated and treats the symptoms accompanying the treated TP (Reilly et al., 2018, 
Gleitz & Hornig, 2012). 
 
The following two types of extracorporeal shockwaves may be generated (Figure 2.5), 
namely, radial shockwaves and focused shockwaves. The wave produced by each type of 
shockwave depends on the amount of energy of the wave and this will in turn determine the 
depth of human tissue penetration (Watson, 2015). 
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Figure 2.5 Illustration demonstrating the difference between radial and focused 
shockwaves (Schmidtz, Csaszar, Milz, Schieker, Maffulli, Rompe & Furia, 2015) 
 
Radial shockwaves, also known as soft shockwaves, are produced by pneumatic or ballistic 
devices. These waves are more superficial when compared to focus shockwaves but may 
cover larger areas in the treated segment. Radial waves are generated by the collision of 
solid bodies and may be used on extensive muscle regions. Focused shockwaves, also 
known as hard shockwaves, are produced by electrohydraulic, electromagnetic and 
piezoelectric devices. These waves penetrate deeper than radial shockwaves and they are 
also more effective in treating smaller areas. In addition, they are also more commonly used 
in surgical interventions due to their destructive nature (Reilly et al., 2018, Watson, 2015).  
 
The EMS Dolorcast Smart 2.0 shockwave machine, which generates radial extracorporeal 
shockwaves (Figure 2.6), was used for the purposes of this study. 
 
Figure 2.6 Illustration demonstrating generation of Radial ESWT (EMS 
Dolorclast,1997). 
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Radial shockwaves are more suitable than focused shockwaves for treating superficial tissue 
because the therapeutic effect is based on tissue healing and regeneration (Watson, 2015). 
The acoustic energy produced diverges and spreads more deeply as it penetrates the tissue. 
Maximum energy is released by radial shockwaves as they leave the head of the applicator 
and then decreases as waves spreads to deeper tissue. The energy disappears in and 
around the tissue when it hits the target tissue. Thus, it affects not only the tissue being 
treated but also its surroundings (Nedelka, Nedelka, Schlenker, Hankins & Mazanec, 2014). 
 
2.6 Conclusion  
Activator trigger point therapy or shockwave therapy to treat myofascial trigger points have 
been found to be successful modalities in treating trigger points (Blikstad & Gemmell, 2008, 
Gleitz & Hornig, 2012). The information discussed in this chapter encompassed the basic 
theoretical knowledge required for the various components of the study. 
Trigger points in the glute medius muscle may be caused by numerous factors and, hence, 
the latent or active trigger point will remain if the primary cause is not eliminated. Treatment 
involving activator trigger point therapy or shockwave therapy may help to either improve 
low back pain and or the gluteal pain associated with the glute medius trigger points. 
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CHAPTER 3: METHODOLOGY 
3.1 Introduction 
This chapter discusses the research design and research methods used in the study with 
the chapter elaborating on the participant selection, group allocation, characteristics of the 
groups, assessment of subjective (Numerical Pain Rating Scale and McGill Pain 
Questionnaire) and objective (pressure algometer) measurements, the treatment protocol 
and follow up treatments used. 
 
3.2 Study Design 
This study was both quantitative and comparative in design. Convenient sampling and 
random group allocations were used. 
 
3.3 Participant Recruitment 
The study participants were recruited from students, patients and members of the public who 
presented to the University of Johannesburg Chiropractic Clinic and who met the inclusion 
criteria. After the Research Ethics Committee of the University of Johannesburg had 
approved the study, permission was requested from and granted by Dr C. Nonkwelo to 
commence the study (Appendix A). The participants were recruited through both word of 
mouth and the placement of advertisements (Appendix B) within and around the chiropractic 
clinic and the campus.  
The researcher explained the study to potential participants. The participants received an 
information letter (Appendix C) and a consent form (Appendix D) which they were required 
to read and sign. The study was conducted at the Chiropractic Clinic on the Doornfontein 
Campus of the University of Johannesburg. 
 
3.4 Sample Selection and Size 
Thirty participants who met both the inclusion and the exclusion criteria were randomly and 
equally divided into two groups. Each group consisted of fifteen participants. Group 1 
received activator trigger point therapy to the identified glute medius trigger point while group 
2 received shockwave therapy. Randomisation was ensured by the participants drawing a 
number allocated to either group 1 or group 2 from a container.  
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3.4.1 Inclusion criteria 
In order to be included in this study participants had to meet the following criteria: 
• Male or female 
• Between the ages of 18 and 50 years. People older than 50 years were excluded 
as any degenerative conditions would have altered the results of the study (Fujiwara, 
Lim, An, Tanaka, Jeon, Anderson & Haughton, 2000) 
• History of non-specific low back pain 
• Presence of an active trigger point which may have caused spontaneous local or 
referred pain and paraesthesia in the glute medius muscle (Gleitz & Hornig, 2012)  
• Meet the diagnostic criteria for an active trigger point in the glute medius muscle 
(Appendix F) 
 
3.4.2 Exclusion criteria 
To be excluded from the study individuals had to meet the following criteria: 
• Present contraindications to shockwave therapy (Appendix E). 
• Taking any anti-inflammatory medication or pain killers as this may have affected 
the results of the study. 
• Already undergoing treatment for non-specific low back pain or glute medius trigger 
points as this would have affected the results of the study. 
 
3.5 Group Allocation 
Participants who had met the specific inclusion criteria and were willing to participate in the 
study were then randomly and equally divided into two groups. Each participant had to draw 
a card that was numbered either one or two from a container with the number drawn 
determining to which group the participant belonged. In order to eliminate bias and results 
being changed, the participants did not know to which group the numbers referred and, 
therefore, they could not choose which group they wanted to be in. 
• Group 1 (15 participants) received activator trigger point therapy to the identified 
trigger point in the glute medius muscle. 
• Group 2 (15 participants) received shockwave therapy to the identified trigger point 
in the glute medius muscle. 
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3.6 Treatment Approach 
During the recruitment stage potential participants were asked to read the information form 
(Appendix C). Once they had agreed on the terms stipulated in the information sheet they 
had required to read and sign the consent form before being invited to the first consultation. 
A total of seven consultations over a three-week period was required depending on the 
availability of the participant. 
  
3.6.1 First and follow-up consultations 
a. Initial consultation  
At the initial consultation the participants were asked to read and sign the consent form 
(Appendix C). The participants then drew a number from the container in order to be 
allocated to either group 1 or group 2. A full case history (Appendix G), physical examination 
(Appendix H), lumbar spine regional (Appendix I) and examination of the glute medius 
muscle was then performed by the researcher.  
 
The findings were summarised in the subjective/objective/assessment/protocol (S.O.A.P) 
notes (Appendix J). The subjective and objective data had to be collected before starting the 
treatment. The subjective questionnaires included the McGill Pain Questionnaire (MPQ) 
(Appendix K) and the numerical pain rating scale (NPRS) (Appendix L) while the objective 
measurements included three pain readings were taken by the researcher with a handheld 
pressure algometer over the identified glute medius trigger point. These readings were then 
recorded in a table (Appendix M).  
 
b. Follow-up consultations 
During each follow up consultation, the glute medius trigger points were assessed using flat 
palpation followed by treatment involving either activator trigger point therapy (group 1) or 
shockwave therapy (group 2). A total of six treatments took place over a three-week period. 
During the seventh consultation measurements were recorded. Subjective and objective 
measurements were recorded during the fourth and seventh visits. 
3.6.2 Treatment 
Each participant underwent a myofascial trigger point examination. The examination was 
conducted with the participant lying prone.  
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In this position the glute medius muscle is easily accessible and relaxed, thus allowing the 
researcher to effortlessly identify any taut bands in the muscle belly by comparing the one 
side to the other. Palpation enabled the researcher to identify a taut band in the glute medius 
muscle belly with the trigger point being palpated for local tenderness with a focal point and, 
in certain cases, a characteristic referral pattern. After the trigger point had been identified it 
was indicated with a marker, thus ensuring that the same trigger point was treated at every 
visit. Either activator trigger point therapy or shockwave therapy was administered to the 
trigger point.  
 
3.6.3 Intervention 
a. Activator trigger point therapy 
The participants in group 1 received activator trigger point therapy to the most active trigger 
point that had been identified in the glute medius muscle. Each participant was requested to 
lie prone with his arms at the side of the body. The treatment was administered by placing 
the handheld device (Figure 3.1) perpendicular to the trigger point which had been identified. 
The average force range (AFR) is between 20 to 45 AFR. However, during the study the 
device was set at 35 AFR as deeper muscles require a higher AFR to obtain the desired 
effect. Ten thrusts were administered at a rate of one thrust per second over the identified 
trigger point in accordance with the standard treatment protocol for using activator trigger 
point therapy (Blikstad & Gemmell, 2008). 
 
 
 
Figure 3.1 Activator instrument (JTECH Medical, 2016) 
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b. Shockwave therapy 
The participants in group 2 received shockwave therapy to the most active trigger point 
identified in the glute medius muscle. Each participant was requested to lie prone with his 
arms at the side of the body. The treatment was administered by placing the head of the 
device (Figure 3.2) over the trigger point which had been identified, As suggested by Ramon 
et al. (2015), 1000 shocks at an energy level of 2 bar and a shockwave frequency of 12 Hz 
were administered.  
 
 
Figure 3.2 The Swiss Dolorcast Smart 2.0 ESWT unit (EMS Dolorclast, 1997). 
 
3.7 Subjective Data 
The two questionnaires that were used to record and verify the subjective data changes in 
the participants’ experience of the low back and or gluteal pain over the three-week time 
period were the McGill Pain Questionnaire (Appendix K) and the numerical pain rating scale 
(Appendix L). The participants completed the questionnaires during the first, fourth and 
seventh consultations. 
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3.7.1 McGill Pain Questionnaire 
The MPQ uses 15 pain descriptors to assess the sensory, affective and evaluative qualities 
of pain. The questionnaire includes a variety of sub-classes which describe the different 
types of pain.  
The participants selected the pain descriptor that they deemed to be the most relevant and 
which best described their pain or sensations at the time. In addition, they had to rate the 
sensation they experienced on a scale ranging between 0 (no pain) to 3 (severe pain). 
According to Dworkin, Turk, Revicki, Coyne, Pierce-Sander, Bhagwat, Everton, Burke and 
Cowan (2009), the reliability and validity of MPQ are well established.  
 
3.7.2 Numerical Pain Rating Scale  
The NPRS is a unidimensional measure of pain intensity in adults and the pain improvement 
experienced. The participants had to rate their pain out of ten, from 0 (no pain) to 10 (pain 
as severe as you are able to imagine or the worst pain imaginable). Pain was scored during 
the first, fourth and seventh visits. NPRS is considered to be a valid and reliable measure of 
pain (Hawker, Mian, Kendzerska & French, 2011). 
 
3.8 Objective Data 
3.8.1 Pressure algometer 
Myofascial pain syndrome is diagnosed by measuring muscle tenderness. The pressure 
algometer (Figure 3.3) is a handheld device which is used to measure the deep pressure 
pain threshold, tenderness resistance and severity of a myofascial trigger point. The device 
comprises a rubber disc that is placed perpendicular and in contact with the patient’s skin. A 
force gauge that measures in kilograms of pressure per square centimetre (kg/cm²) when 
light pressure is applied. The pain threshold is deemed to be abnormal when the site 
measures 2 kg/cm² less than that measured on the opposite site (Giburm, Chan, Si Bog, Mi 
Jung & Seong, 2011). 
 
The pain pressure algometer was used to objectively obtain the pain readings on the active 
glute medius trigger points. Three measurements were taken during the first, fourth and 
seventh consultations and recorded in a table (Appendix M). The participants were required 
to lie face down (prone) on the examination table so as to allow the gluteal area to be 
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adequately exposed. Active trigger points were identified using flat palpation and the most 
active and tender trigger point was indicated with a marker. The algometer was placed in 
direct contact with the skin over the trigger point identified and pressure was subsequently 
applied slowly in the direction of the trigger point. 
The participants were then asked to verbally indicate the first sensation of pain or discomfort. 
Three sequential readings were taken in order to determine an average reading. The same 
trigger point was used during each consultation and the measurements were recorded in 
kg/cm². 
 
 
Figure 3.3 Pressure algometer (Buhagiar, Cassar, Brincat, Buttigieg, Inglott, Adami & 
Azzopardi, 2011) 
 
The pressure algometer is considered to be a valid and reliable parameter which may be 
used to assess the effects of treatment of both myofascial pain syndrome and other 
musculoskeletal pain (Park, Kim, Park, Kim & Jang, 2011). 
 
3.9 Data Analysis 
Once the researcher had collected and captured the subjective and objective data required 
for the study, the information was analysed by Mr. Anesu Kuhudzai from the STATKON 
Department at the University of Johannesburg. The statistician used the following tests: 
• Shapiro-Wilk test to check normality of the variables. 
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• Intra-group analysis (comparison within each group) was performed using the 
Friedman test to measure possible statistically significant changes over time. If 
statistical changes were noted, then the Wilcoxon signed rank test was used to 
check statistically significant changes between two time periods. 
• Inter-group analysis (comparison between the two groups) was performed using 
the Mann-Whitney tests to check statistically significant changes between the two 
groups. 
The results of the abovementioned tests were interpreted by the researcher who then drew 
the necessary conclusions. 
 
3.10 Ethical Considerations 
All the participants who were interested in participating in the study were requested to read 
and sign the information letter (Appendix C) as well as the consent form (Appendix D) which 
were specific to this study. The information and consent forms provided the name of the 
researcher, the purpose of the study, the benefits of participation in the study, participant 
assessment and treatment procedure. Any risks, benefits and discomforts related to the 
treatments involved were also explained in the forms (Appendix C). It was also stated that 
the participants’ safety would be ensured (prevention of harm). The information letter also 
highlighted that participation in the study was voluntary and that the participants would be 
allowed to withdraw from the study at any stage, without consequences. If the participants 
had any further questions, these were answered and explained by the researcher whose 
contact details were indicated on the forms. The participants were then required to sign the 
information letter and the consent form, thus signifying that they understood what would be 
required of them during the study. The results of the study would be made available on 
request. The study data was accessible to both the researcher and STATKON and may be 
used for publication purposes. 
 
The study involved the following risks and discomforts, namely, slight discomfort and pain 
during and after the treatment in the lower back and upper gluteal region. However, this is a 
normal response that may occur after shockwave and activator trigger point therapy. There 
was also a possibility that the participants who received shockwave therapy could present 
light bruising a few days after treatment. However, this is normal and should resolve within 
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a few days. The possible benefits of the study included pain relief in the low back and gluteal 
region, an increase in the range of motion as well as an increase in mobility.  
   
 
If any concerns had arisen during the study, the supervising clinician would have been 
notified immediately. Should they have deemed it necessary, the participant would have 
been referred to the relevant health care professional.  
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CHAPTER 4: RESULTS 
4.1 Introduction 
This chapter contains a discussion of the data that was collected during the clinical trial 
performed during the study. The data was collected over seven visits to the Chiropractic 
Clinic at the University of Johannesburg. The sample group comprised thirty participants 
who divided into two groups of fifteen participants each. Group 1 received activator trigger 
point therapy administer to the glute medius TP and group 2 received shockwave therapy 
administer to the glute medius TP. In view of the small sample size it was not possible to 
make any assumptions concerning the population as a whole. 
 
Both subjective and objective data was analysed to determine whether there had been any 
statistical improvement between the two groups over the time period in question and, 
furthermore, to ascertain where the improvement had occurred.  
 
The analysis of this clinical trial was performed using data that had been recorded during 
visits one, four and seven. The following analyses were conducted: 
• Demographic data analysis 
➢ Inter-group age and gender analysis 
• Subjective data analysis  
➢ Numerical Pain Rating Scale 
➢ McGill Pain Questionnaire 
• Objective data analysis 
➢ Pressure pain algometer 
 
4.1.1 Intragroup analysis: 
The Shapiro-Wilk test was used to check for normality in each group This test is used for 
sample sizes comprising fewer than fifty participants. Normality tests are performed to 
determine whether parametric or non-parametric testing will be required to further analyse 
the data. However, no normality was identified and, hence, non-parametric testing was 
required. The Friedman test is a non-parametric test that was carried out to determine 
statistical differences within each group at every visit. If statistical significance was found the 
Wilcoxon signed rank test was then used to ascertain where these changes had occurred.  
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4.1.2 Intergroup analysis 
The Mann-Whitney U test was used to conduct the intergroup analysis. This is a non-
parametric test which was used due to the irregular spread of the statistics in the study. This 
test identified statistical significance, specifically between the two groups on visits one, four 
and seven. A probability value (p-value) of 0.05 was set to determine the significance level 
of the results produced. If the p-value were ≤ 0.05 this would have indicated that the data 
was not normally distributed, that there was a difference between the two groups over time 
and that the data was statistically significant. On the other hand, if the p-value were greater 
than 0.05 (p > 0.05) this would have indicated that the data was normally distributed between 
the two groups and that no changes had occurred over the time period, hence no statistical 
difference although the data may still have clinical value. 
 
4.2 Demographic Data Analysis 
4.2.1 Age and gender analysis 
 
Table 4.1 Demographic data analysis of age and gender 
Characteristics Group 1 Group 2 Total 
Sample size (n) 15 15 30 
Age 
Mean 26.6 24.9 25.7 
Stdev 7.74 2.29 5.68 
Min 19 22 19 
Max 51 30 51 
Median 24 24 24 
Gender 
Male count 3 6 9 
Male % 20% 40% 30% 
Female count 12 9 21 
Female % 80% 60% 70% 
Total/combined 15 15 30 
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As indicated in table 4.1, the sample comprised 30 participants with 15 participants in each 
group. Of the total number of participants 21 (70%) were females and 9 (30%) males. The 
overall age of the participants ranged between 19 and 51 years old. 
Group 1 analysis: 
The youngest participant in this group was 19 years old and the oldest 51 years old, with a 
mean age of 26.6 years old. The group consisted of 3 (20%) males and 12 (80%) females. 
Group 2 analysis: 
The youngest participant in this group was 22 years old and the oldest 30 years old, with a 
mean age of 24.9 years old. The group consisted of 6 (40%) males and 9 (60%) females. 
 
4.3 Subjective Data Analysis 
The subjective data included the Numerical Pain Rating Scale (NPRS) and the McGill Pain 
Questionnaire (MPQ). 
4.3.1 Numerical Pain Rating Scale (NPRS) 
 
Table 4.2 Group means and standard deviation of visit 1 and visit 7 for NPRS: 
Differences between groups and differences within groups 
    Visit 1 Visit 7 
Percentage 
change 
between 
visit 1 and 
visit 7 
Difference 
within the 
groups 
(p-value) 
Statistical 
significance 
Group 1 
n = 15 
Mean 5.73 1.80 
69% 0.001 Significant Stdev 1.16 1.52 
Group 2 
n = 15 
Mean 5.33 1.33 
75% 0.050 Significant Stdev 1.29 1.99 
Difference 
between 
groups  
(p-value)  0.304 0.138     Not significant  
 
Table 4.2 above presents the values of the subjective data derived from the NPRS. The 
mean NPRS readings for group 1 were 5.73 on visit 1 and 1.80 on visit 7 while the mean 
NPRS readings for group 2 were 5.33 on visit 1 and 1.33 on visit 7.  
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Table 4.2 shows that both the groups revealed an overall decrease in pain between 
treatments 1 and 7 with group 1 demonstrating a pain decrease of 69% and group 2 a pain 
decrease of 75% over the duration of the study period. 
a) Intra-group analysis of the NPRS: 
The non-parametric Friedman test and the Wilcoxon signed rank tests were used for the 
intra-group analysis to determine whether there had been a change within each group over 
the time period. As shown in table 4.2 above, the Friedman test revealed a statistical 
significance over time in both the groups: group 1 with a p-value of 0.001 (p ≤ 0.05) and 
group 2 with a p-value of 0.05 (p ≤ 0.05). As the Friedman test revealed statistical 
significance, the next step was to determine where the changes in pain had occurred. Thus, 
the Wilcoxon signed rank tests were used to determine these changes. 
 
The Bonferroni adjustment was applied to the Wilcoxon signed rank test to prevent the data 
from appearing incorrectly. In line with Bonferroni adjustment, the p-value of 0.05 was 
divided by the number of tests used, hence a revised p-value of 0.025. A p-value of ≤ 0.025 
suggests statistical significance. 
 
Table 4.3 Wilcoxon signed rank test for NPRS readings of groups 1 and 2 over visits 
1 to 4 and 1 to 7 
Comparison  
of visits 
p-values 
Group 1 Group 2 
1–4 0.001 0.006 
1–7 0.001 0.001 
 
As shown in table 4.3, group 1 and group 2 both showed statistical significance for the NPRS 
with p-values well below 0.025. Group 1 had a p-value of 0.001 (p≤0.025) between visits 1 
and 4 and a p-value of 0.001 (p ≤ 0.025) between visits 1 and 7 while Group 2 had a p-value 
of 0.006 (p ≤ 0.025) between visits 1 and 4 and a p-value of 0.001 (p ≤ 0.025) between visits 
1 and 7.     
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b) Inter-group analysis of the NPRS:  
As seen in the intra-group analysis the Wilcoxon signed rank test proved statistical 
significance. The non-parametric Mann Whitney U test was used to determine what the 
differences were that had occurred between the two groups. 
 
As shown above in table 4.2, the Mann Whitney U test revealed no significant statistical 
difference on visit 1 with a p-value of 0.304 (p > 0.05) and on visit 7 with a p-value of 0.138 
(p > 0.05). Both the groups were comparable at the start and over time they had improved 
at a similar rate. 
 
4.3.2 McGill Pain Questionnaire (MPQ) 
 
Table 4.4 Group 1 means and standard deviation on visit 1 and visit 7 for MPQ: 
Differences within groups 
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 d
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Aching 1.13 1.18 0.33 0.90 70.59% 0.004 Significant 
Cramping 1.20 1.01 0.13 0.35 89.17% 0.000 Significant 
Gnawing 0.13 0.51 0.07 0.25 46.15% 0.368 Not Significant 
Sharp 0.73 1.03 0.00 0.00 100% 0.005 Significant 
Shooting 0.33 0.61 0.00 0.00 100% 0.018 Significant 
Tender 1.60 1.05 0.53 0.64 66.88% 0.004 Significant 
Throbbing 0.47 0.74 0.27 0.70 42.55% 0.018 Significant 
 
Table 4.4 presents shows the values of the subjective data derived from the MPQ for group 
1 only.  
• Aching type pain had a mean value of 1.13 on visit 1 and a mean value of 0.33 on 
visit 7. The average aching pain improvement was 71% from visit 1 to visit 7.  
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• Cramping type pain had a mean value of 1.20 on visit 1 and a mean value on 0.13 
at visit 7. The average cramping pain improvement was 89% from visit 1 to visit 7.  
• Gnawing type pain had a mean value of 0.13 on visit 1 and a mean value on 0.07 
on visit 7. The average gnawing pain improvement was 46% from visit 1 to visit 7.  
• Sharp type pain had a mean value of 0.73 on visit 1 and a mean value on 0.00 on 
visit 7. The average sharp pain improvement was 100% from visit 1 to visit 7.  
• Shooting type pain had a mean value on 0.33 at visit 1 and a mean value of 0.00 on 
visit 7. The average shooting pain improvement was 100% from visit 1 to visit 7.  
• Tender type pain had a mean value of 1.60 on visit 1 and a mean value of 0.53 on 
visit 7. The average tender pain improvement was 67% from visit 1 to visit 7.  
• Throbbing type pain had a mean value of 0.47 on visit 1 and a mean value of 0.27 
on visit 7. The average throbbing pain improvement was 43% from visit 1 to visit 7. 
 
Table 4.5 Group 2 means and standard deviation of visit 1 and visit 7 for MPQ: 
Differences within groups 
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Aching 2.00 0.75 0.27 0.79 86.50% 0.000 Significant 
Cramping 1.00 1.13 0.00 0.00 100% 0.002 Significant 
Gnawing 0.67 0.97 0.00 0.00 100% 0.014 Significant 
Sharp 0.73 1.10 0.07 0.25 90.41% 0.015 Significant 
Shooting 0.33 0.90 0.00 0.00 100% 0.223 Not Significant 
Tender 1.13 1.30 0.53 0.74 53.10% 0.020 Significant 
Throbbing 0.27 0.70 0.00 0.00 100% 0.135 Not Significant 
 
Table 4.5 above presents the values of the subjective data derived from the MPQ for group 
2 only.  
• Aching type pain had a mean value of 2.00 on visit 1 and a mean value of 0.27 on 
visit 7. The average aching pain improvement was 87% from visit 1 to visit 7.  
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• Cramping type pain had a mean value of 1.00 on visit 1 and a mean value of 0.00 
on visit 7. The average cramping pain improvement was 100% from visit 1 to visit 7.  
• Gnawing type pain had a mean value of 0.67 on visit 1 and a mean value of 0.00 on 
visit 7. The average gnawing pain improvement was 100% from visit 1 to visit 7.  
• Sharp type pain had a mean value of 0.73 on visit 1 and a mean value of 0.07 on 
visit 7. The average sharp pain improvement was 90% from visit 1 to visit 7.  
• Shooting type pain had a mean value of 0.33 on visit 1 and a mean value of 0.00 on 
visit 7. The average shooting pain improvement was 100% from visit 1 to visit 7.  
• Tender type pain had a mean value of 1.13 on visit 1 and a mean value of 0.53 on 
visit 7. The average tender pain improvement was 53% from visit 1 to visit 7.  
• Throbbing type pain had mean value of 0.27 on visit 1 and a mean value of 0.00 on 
visit 7. The average throbbing pain improvement was 100% from visit 1 to visit 7. 
 
a) Intra-group analysis of the MPQ: 
The non-parametric Friedman test and the Wilcoxon signed rank tests were used for the 
intra-group analysis to determine whether there had been a change within each group over 
time. As shown in tables 4.4 and 4.5 above, the following pain descriptions showed a 
statistical significance in both groups with a p-value of less than or equal to 0.05. 
Group 1: 
• Aching: p-value 0.004 (≤ 0.05) 
• Cramping: p-value 0.000 (≤ 0.05) 
• Sharp p-value: 0.005 (≤ 0.05) 
• Shooting p-value: 0.018 (≤ 0.05) 
• Tender p-value: 0.004 (≤ 0.05) 
• Throbbing: 0.018 (≤ 0.05) 
Gnawing type pain was shown to be non-statistically significant in group 1 with a p-value > 
0.05. 
Group 2: 
• Aching: p-value 0.000 (≤ 0.05) 
• Cramping: p-value 0.002 (≤ 0.05) 
• Gnawing: p-value 0.014 (≤ 0.05) 
• Sharp: p-value 0.015 (≤ 0.05) 
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• Tender: p-value 0.020 (≤ 0.05) 
Throbbing and shooting type pain were shown to be non-statistically significant in group 2 
with a p-value > 0.05. 
The Friedman test showed statistical significance in each of the pain descriptives explained 
above in each of the groups. Hence, the next step was to determine where the changes in 
pain had occurred. The Wilcoxon signed rank tests were used to determine these changes. 
The Bonferroni adjustment was applied to the Wilcoxon signed rank test to prevent the data 
from appearing incorrectly. In line with the Bonferroni adjustment, the p-value of 0.05 was 
divided by the number of tests used, hence a revised p-value of 0.025. A p-value of ≤ 0.025 
suggests statistical significance. 
 
Table 4.6 Wilcoxon signed rank test for MPQ readings for groups 1 and 2 over visits 
1 to 4 and 1 to 7 
Pain descriptive 
p-value 
Group 1 Group 2 
1 to 4 1 to 7 1 to 4 1 to 7 
Aching 0.023 0.014 0.002 0.001 
Cramping 0.011 0.004 0.024 0.011 
Gnawing 1.000 0.317 0.063 0.025 
Sharp 0.038 0.026 0.066 0.039 
Shooting 0.059 0.059 0.317 0.18 
Tender 0.356 0.006 0.914 0.047 
Throbbing 0.102 0.038 0.705 0.157 
 
As shown in table 4.6 group 1 showed statistical significance for the following pain 
descriptives between visits 1 and 7. 
• Aching: p-value of 0.014 (≤ 0.25) 
• Cramping: p-value of 0.004 (≤ 0.25) 
• Tender: p-value of 0.006 (≤ 0.25) 
In table 4.6 group 2 showed statistical significance for the following pain descriptives 
between visits 1 and 7. 
• Aching: p-value of 0.001 (≤ 0.25) 
• Cramping: p-value of 0.011 (≤ 0.25) 
• Gnawing: p-value of 0.025 (≤ 0.25) 
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• Shooting: p-value of 0.18 (≤ 0.25) 
 
Appendix Q contains the group means and standard deviations of visit 1 and visit 7 for the 
MPQ and the differences within the groups for all the data that appeared to be statistically 
insignificant. All the data presented in Appendix Q proved to be statistically insignificant as 
all the p-values were greater than 0.05 (p>0.05). In addition, some of the pain descriptives 
had no p-value as no participants had presented with this type of pain. 
 
b) Inter-group analysis of the MPQ: 
As seen in the intra-group analysis the Wilcoxon signed rank test proved the presence of a 
degree of statistical significance. The non-parametric Mann Whitney U test was used to 
determine the differences between the two groups. 
 
Table 4.7 Non-parametric Mann-Whitney U test results for MPQ 
Pain descriptive 
Difference between groups  
(p-value) Statistical 
significance 
Visit 1 Visit 7 
Aching 0.041 0.972 Not significant 
Cramping 0.624 0.539 Not significant 
Gnawing 0.217 0.775 Not significant 
Sharp 0.902 0.775 Not significant 
Shooting 0.494 1.000 Not significant 
Tender 0.357 0.87 Not significant 
Throbbing 0.274 1.000 Not significant 
Exhausting 0.976 0.317 Not significant 
Fearful 1.000 1.000 Not significant 
Heavy 1.000 0.524 Not significant 
Hot and burning 0.524 1.000 Not significant 
Punishing – cruel 0.317 1.000 Not significant 
Sickening 0.962 0.317 Not significant 
Splitting 1.000 1.000 Not significant 
Stabbing 0.605 1.000 Not significant 
 
As shown in table 4.7 above, the Mann Whitney U test revealed no statistical significance 
difference between visit 1 and visit 7 with all p-value being greater than 0.05 (p > 0.05). Both 
groups were comparable at the start and, over time, they improved at a similar rate. 
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4.4 Objective Data Analysis 
4.4.1 Pain pressure algometer (PPA) 
The objective data is represented by the values derived from the PPA. 
 
Table 4.8 Group means and standard deviation on visit 1 and visit 7 for PPA: 
Differences between groups and differences within groups 
     
 
 
Visit 1 
 
 
 
Visit 7 
Percentage 
change 
between 
visit 1 and 
visit 7 
Difference 
within the 
groups  
(p-value) 
Statistical 
significance 
Group 1 Mean 2.54 3.36 32% 0.000 Significant 
Stdev 0.51 0.78 
Group 2 Mean 2.68 4.06 51% 0.004 Significant 
Stdev 0.63 1.14 
Difference 
between 
groups  
(p-value) 
 
  
0.740 
 
0.078  
     
Not significant  
 
As indicated in table 4.8, the mean value of group 1 was 2.54 kg/cm² on visit 1 and 3.36 
kg/cm² on visit 7, while the mean values of group 2 were 2.68 kg/cm² on visit 1 and 4.06 
kg/cm² on visit 7. Both the groups showed an overall increase in kg/cm between treatments 
1 and 7. Group 1 had a pain improvement of 32% and group 2 a pain improvement of 51% 
between visits 1 and 7. 
 
a) Intra-group analysis 
The non-parametric Friedman test and the Wilcoxon signed rank tests were used for the 
intra-group analysis to determine whether there had been a change within each group over 
time. As shown in table 4.8 above, the Friedman test revealed a statistical significance over 
time in both the groups: group 1 with a p-value of 0.000 (p ≤ 0.05) and group 2 with a p-
value of 0.004 (p ≤ 0.05).  
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Thus, in view of the fact that the Friedman test had showed statistical significance, the next 
step was to determine where the changes in pain had occurred with the Wilcoxon signed 
rank tests being used to determine this. 
The Bonferroni adjustment was applied to the Wilcoxon signed rank test to prevent the data 
from appearing incorrectly. In line with the Bonferroni adjustment, the p-value of 0.05 was 
divided by the number of tests used, hence a revised p-value of 0.025. A p-value of ≤ 0.025 
suggests statistical significance. 
 
Table 4.9 Wilcoxon signed rank test for PPA readings of groups 1 and 2 over visits 1 
to 4 and 1 to 7 
Comparison 
Between visits 
p-values 
Group 1 Group 2 
1 – 4 0.099 0.099 
1 - 7 0.001 0.002 
 
As shown in table 4.9 above, both group 1 and group 2 showed statistical significance for 
the PPA with p-values below 0.025. However, group 1 had a p-value of 0.099 (p ≥ 0.025) 
between visits 1 and 4 which indicated non-significant statistical value while the p-value of 
0.001 (p ≤ 0.025) between visits 1 and 7 indicated statistical significance. Group 2 had a p-
value of 0.099 (p ≥ 0.025) between visits 1 and 4 which indicated non-significant statistical 
value while the p-value of 0.002 (p ≤ 0.025) between visits 1 and 7 indicated statistical 
significance. Thus, both groups showed a statistical significance between visits 1 and 7. 
 
b) Inter-group analysis: 
As seen in the intra-group analysis the Wilcoxon signed rank test proved statistical 
significance between visits 1 and 7 for both groups. The non-parametric Mann Whitney U 
test was then used to determine what these differences were that had occurred between the 
two groups. 
As shown in table 4.8 above, the Mann Whitney U test revealed no significant statistical 
difference on visit 1 with a p-value of 0.740 (p ≥ 0.05) and with a p-value of 0.078 (p ≥ 0.05) 
on visit 7. Both the groups were comparable at the start and, over time, improved at a similar 
rate. 
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CHAPTER 5: DISCUSSION 
5.1 Introduction 
This chapter presents a discussion on the demographic data, subjective data and objective 
data that was collected during the study and which was referred to in Chapter 4. Clinical 
reasoning was used to interpret the data collected with the aim of determining whether 
activator trigger point therapy or shockwave therapy had proved to be most effective in 
treating glute medius trigger points. 
 
5.2 Demographical Data 
The study comprised of 30 male and female participants between the age of 19 and 51 years. 
The group included 21 females and 9 males. There were 12 females and 3 males in group 
1. The ages of these particpants ranged between 19 and 51 years with a mean age of 26.6. 
Group 2 comprised 9 females and 6 males. The ages of these participants ranged between 
22 and 30 years with a mean age of 24.9. 
 
This data presented in the previous paragraph indicated that the age distribution was more 
or less evenly distributed between the two groups with the majority of the participants being 
in their mid to late 20s. This may be explained by the fact that the study was conducted at 
the Chiropractic Clinic of the University of Johannesburg and, thus,the majority of the 
particpants were either students and/or people visiting the clinic.  
 
Patients with myofascial pain syndrome often present with myofascial trigger points. It is said 
that in the traditional population myofascial TPs have a lifetime prevelance of 85% (Lluch, 
Nijs, De Kooning, Van Dyck, Vandersraeten, Struyf & Roussel, 2015). At some point in their 
lives, 80% of adults suffer from low back pain that affects both their physical capacity and 
pyschosocial health (Sharan et al., 2014). 
 
It may, therefore, be concluded that the population represented in the sample may be 
compared to the general population which often suffers from low back pain due to myofascial 
TPs. 
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5.3 Subjective Data 
Two types of methods were used to analyse the subjective data which had been collected. 
The NPRS and the MPQ was used to determine the pain levels that each participant 
experienced due to the glute medius trigger point or non-specific low back pain. 
 
5.3.1 NPRS 
a. Descriptive statistical analysis  
As indicated in table 4.2 the numerical pain rating scale score for group 1 showed an initial 
mean value of 5.73 and a final mean value of 1.80 with the percentage change between the 
initial and final mean values showing a decrease of 69%. On the other hand, group 2 showed 
an initial mean value of 5.33 and a final mean value of 1.33. with the percentage change 
between the initial and final mean values showing a decrease of 75%. Based on these results 
it could be concluded that, compared to group 1, group 2 experienced a better pain 
improvement in respect of the NPRS. 
 
b. Intragroup analysis of NPRS 
The non-parametric Friedman test was used for both groups for the intra-group analysis of 
the NPRS to determine changes in the mean values during the seven visits. Table 4.2 
revealed that group 1 had a p-value of 0.001 and group 2 a p-value of 0.050 with both groups 
showing statistical significance with a p-value ≤0.05. 
In view of the occurrence of the statistical significance detected by the Friedman test a further 
investigation was carried out. The Wilcoxon signed rank test, together with the Bonferroni 
adjustment, were used to determine where these changes had occurred. As indicated in 
table 4.3 groups 1 and 2 had a p-value of 0.001 between visits 1 and 7 – ≤ 0.025. This finding 
indicated that statistically significant changes in both groups over time. 
 
c. Intergroup analysis of NPRS 
For the purposes of the inter-group analysis, the non-parametric Mann-Whitney U test was 
used to determine the difference between the two groups. As indicated in table 4.2, the p-
value for visit 1 was 0.304 and 0.138, for visit 7, thus suggesting no statistical significance 
difference between the groups as all the p-values were > 0.05. Thus, the results from the 
NPRS showed that the participants in both groups had improved in a similar way. 
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d. Discussion of the NPRS 
As discussed in Chapter 3, the participants had to rate their pain level on a scale from zero 
to ten, with zero indicating no pain and ten indicating the worst pain ever experienced. 
Hence, a higher rating on the scale indicated a higher pain intensity and vice versa. 
According to the literature, a two-point or more change in the NPRS over time is considered 
to be of clinical importance (Farrar, Young, La Mareaux, Werth & Poole, 2001). 
 
Based on the descriptive statistics, group 1 showed a 69% improvement and group 2 a 75% 
improvement over the 7 visits, thus conclude that group 2 showed greater improvement in 
relation to pain during the research trial. It emerged from the intra-group analysis that both 
treatment methods had proved to be statistically significant with p-values of ≤ 0.05 while the 
inter-group analysis had showed no statistical significance. Based on these results it may be 
concluded that neither of the groups had showed superior results and that both treatments 
had been effective in treating the glute medius trigger points. 
 
Previous research has demonstrated a positive effect on patient perception based on the 
NPRS. The Visual Analog Scale (VAS) has also been used in previous studies for the 
collection of subjective data and is similar to the NPRS in that it uses a graphic scale that 
ranges from “no symptoms” to “ worst imaginable degree of symptoms” (Phan, Blome, Fritz, 
Gerss, Reich, Ebata & Augustin, 2015).  
 
The results of this study may be compared to the findings of a study conducted by Blikstad 
and Gemell (2008) that tested the immediate effect of activator trigger point therapy versus 
myofascial band therapy in patients presenting with non-specific neck pain and upper 
trapezius trigger points. The study showed a significant decrease in the pain perception of 
the patients who had received activator trigger point therapy. This supports the finding of this 
study and explains the 69% improvement in the pain experienced by those participants who 
were allocated to group 1 and who received activator trigger point therapy to the glute medius 
trigger point identified. 
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Ji, Kim and Han (2012) conducted a study during which four sessions of EWST were applied 
to a trapezius TP over a two-week period. The results showed a 26.4% reduction in the pain 
levels experienced by the participants.  
Shockwave therapy results in a greater pressure stimulus, thus increasing the effect on the 
pain gate due to the fact that pressure receptors are more myelinated than pain receptors. 
Thus, pressure receptors carry pressure stimuli faster than pain receptors are able to do, 
thereby resulting in the closure of the pain gate (Tsoa, 2007). This could be a possible 
explanation for the 75% clinical improvement in pain seen in group 2.  
 
5.3.2 McGill Pain Questionnaire (MPQ) 
a. Descriptive statistical analysis 
As indicated in tables 4.4 and 4.5 and Appendix Q, group 1 presented an average 
improvement of 84.16% in the following pain descriptives: aching, cramping, gnawing, sharp, 
shooting, tender, throbbing, exhausting, heavy, hot and burning, punishing-cruel, sickening 
and stabbing. On the other hand, group 2 presented an average improvement of 86% in the 
following pain descriptives: aching, cramping, gnawing, sharp, shooting, tender, throbbing, 
exhausting, heavy, hot and burning and stabbing. 
 
The following pain descriptives presented with no values, thus indicating that not one of the 
participants had presented with these symptoms and, therefore, no average could be 
calculated – group 1: fearful and splitting and group 2: fearful, punishing – cruel, sickening 
and splitting. 
 
It was concluded from the discussion above that both groups showed improvement over 
time, with group 2 showing a slightly higher improvement rate than group 1. 
 
b. Intragroup analysis of the MPQ 
Tables 4.4 and 4.5 present the results of the Friedman test that was used for the intragroup 
analysis of the MPQ. The following pain descriptives showed a statistically significant 
difference with a p-value of ≤ 0.05: 
• Aching: 0.004 (group 1), 0.000 (group 2)  
o Group 2 showed a more significant improvement of 86.50% 
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• Cramping: 0.000 (group 1), 0.002 (group 2) 
o Group 2 showed a more significant improvement of 100% 
• Gnawing: 0.368 (group 1), 0.014 (group 2) 
o Group 1 – gnawing pain had no statistical significance with p>0.05. 
o  Group 2 showed an improvement of 100% 
• Sharp: 0.005 (group 1), 0.015 (group 2) 
o Group 1 showed a more significant improvement of 100% 
• Shooting: 0.018 (group 1), 0.223 (group 2) 
o Group 2 – shooting pain had no statistical significance. 
o Group 1 showed an improvement of 100% 
• Tender: 0.004 (group 1), 0.020 (group 2) 
o Group 1 showed a more significant improvement of 66.88% 
• Throbbing: 0.018 (group 1), 0.135 (group 2) 
o Group 2 – throbbing pain had no statistical significance. 
o Group 1 showed an improvement of 42.55% 
The MPQ data show a change in the pain experience over time. Group 1 showed greater 
improvement in four pain types, while group 2 showed greater improvement in three pain 
types. However, over the seven visits, both groups showed an improvement percentage with 
respect to the MPQ. 
 
Because the Friedman test showed statistical significance, the non-parametric Wilcoxon 
signed rank test and the Bonferroni adjustment were used to determine where the changes 
had occurred within the two groups. As indicated in table 4.6, the Wilcoxon signed rank test 
indicated statistical significance in some pain descriptives between visit 1 and 7 in both the 
groups, with a p-value ≤0.25. 
 
Between visits 1 to 7, the following pain descriptions had a p-value of less than or equal to 
0.25: 
• Aching: Group 1 – 0.014 and Group 2 – 0.001 
• Cramping: Group 1 – 0.004 and Group 2 – 0.011 
• Tender: Group 1 – 0.006 
• Gnawing: Group 2 – 0.025 
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• Shooting: Group 2 – 0.18 
As indicated in table 4.6, the Wilcoxon signed rank test of the MPQ showed statistical 
significance in both groups, with both showing statistical significance in 7 of the pain 
descriptions and, overall, a decrease in 13 pain descriptions of the 15 listed in the MPQ over 
the time period of the research study. Based on these results one may conclude that activator 
trigger point therapy and shockwave therapy are both effective in treating glute medius 
trigger points.  
 
c. Intergroup analysis of the MPQ 
The Mann-Whitney U test was used to conduct the inter-group analysis of the MPQ. As 
indicated in table 4.7, there was no statistical differences found between the two groups as 
all the p-values for every pain descriptive in the MPQ were > 0.05. It was, therefore, 
concluded that both treatment methods had proved to be effective in treating glute medius 
trigger points although neither method of treatment had been shown to be more effective 
with respect to the subjective data collected using the MPQ. 
 
d. Discussion of the MPQ 
According to the descriptive statistics, group 1 showed a 84.16% improvement and group 2 
a 86% improvement over the seven visits while the intra-group analysis revealed a statistical 
significance in 4 types of pain for group 1 and a statistical significance in 3 types of pain for 
group 2 with p-values ≤ 0.05. In addition, the results of the Wilcoxon signed rank test showed 
that both groups showed a statistical significance in 7 pain types, although the inter-group 
analysis revealed no statistical significance. Based on these results it was concluded that 
neither of the groups showed superior results and, thus, that both treatments were effective 
in treating glute medius trigger points. 
 
The MPQ makes use of 15 pain descriptions that emphasise three aspects of pain, namely, 
motivational affective, cognitive-evaluation and sensory discriminative. Each participant 
experienced a different type of subjective pain (Maire 2002). It emerged from the statistical 
analysis discussed above that neither group 1 nor group 2 was superior to the other group 
as each participant experienced pain in line with his/her pain threshold or feelings at that 
specific point in time.  
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5.4 Objective Data 
5.4.1 Pain pressure algometer 
a. Descriptive statistical analysis 
As indicated in table 4.8, the pain pressure algometer score for group 1 showed an initial 
mean value of 2.549 kg/cm² and a final mean value of 3.364 kg/cm² with the percentage 
change between the initial and final mean values showing a decrease in pain of 32%. On 
the other hand, group 2 showed an initial mean value of 2.689 kg/cm² and a final mean value 
of 4.066 kg/cm². with the percentage change between the initial and final mean values 
showing a decrease in pain of 51%. These results showed that, compared to group 1, group 
2 may have been more effective in increasing the glute medius trigger point pain pressure 
threshold. 
 
b. Intragroup analysis of the pain pressure algometer 
The non-parametric Friedman test was used for both groups for the intra-group analysis of 
the PPA to determine changes in the mean values during the seven visits. Table 4.8 
indicated that group one had a p-value of 0.000 while group 2 had a p-value of 0.004. Thus, 
both groups showed statistical significance with a p-value ≤ 0.05. 
 
In view of the statistical significance detected by the Friedman test a further investigation 
was carried out. The Wilcoxon signed rank test together with the Bonferroni adjustment were 
used to determine where these changes had occurred. As depicted in table 4.9, group 1 had 
a p-value of 0.001 while group 2 had a p-value of 0.002 between visits 1 and 7 – p-values of 
≤ 0.025. Thus, both groups indicated a statistically significant change over time. The findings 
show that both methods of treatment are successful in reducing pain. 
 
c. Intergroup analysis of the pain pressure algometer 
The non-parametric Mann-Whitney U test was used for the purposes of the inter-group 
analysis to determine the difference in the pain pressure threshold between the two groups. 
As indicated in table 4.8, the p-value for visit 1 was 0.740 and for visit 7 0.078, thus 
suggesting no statistical significance difference between the groups as all the p-values were 
> 0.05. Therefore, the PPA findings showed that participants from both groups had improved 
similarly during the time period in question. 
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d. Discussion of the pain pressure algometer 
As revealed by the descriptive statistics group 1 showed a 31% decrease in pain and group 
2 showed a 51% decrease in pain over the seven visits. The intra-group analysis, that 
included the Friedman test and Wilcoxon signed rank test, showed that both treatment 
techniques had been effective in treating glute medius TP with p-values of ≤ 0.05. On the 
other hand, the inter-group analysis showed no statistical significance.  
 
However, clinically the data showed a statistical difference between the two groups with the 
percentage change suggesting that, as compared to group 1, group 2 had a larger impact 
on the pressure pain threshold in respect of the glute medius trigger point that was treated. 
This conclusion was also supported by the patients reviews which were conducted both 
during and after the trials. 
 
Compared to activator trigger point therapy, shockwave therapy delivers greater pressure to 
the area being treated, thereby increasing the effect of the shockwave therapy on the pain 
gate. This suggests that pressure receptors convey pressure sensations much faster than 
do pain receptors, thus resulting in the closure of the pain gate (Tsoa, 2007). 
 
Pressure on a TP, as produced by activator trigger point therapy and shockwave therapy, 
results in hyperaemia as well as an immune response. Vasodilation occurs when the 
pressure is removed, thus causing a decrease in both the height of the TP as well as the 
oxygen and nutrient rich blood to flow to the area, thereby removing inflammatory cells and 
repairing the muscle and its capillaries. This leads to muscle relaxation and a return to the 
normal state. In addition, once a MTP is no longer hypersensitive the pain pressure threshold 
increases (Blikstad & Gemmell, 2008). 
  
5.5 Discussion of results 
In conclusion both groups showed a decrease in pain perception with the NPRS and MPQ 
as well as an increase in the pain threshold. It was therefore concluded that glute medius TP 
may be treated by either activator trigger point therapy or shockwave therapy.  
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Treating a myofascial TP with an activator causes pressure on the TP and resulting in 
lengthening of the contracted sarcomere due to the nociceptive pathway which is being 
stimulated. This results in the release of endorphins and enkephalins which relieve the pain 
caused by the TP (Murphy, 2000). On the other hand, treating myofascial TP with shockwave 
therapy may promote angiogenesis, increase perfusion, enhance cell differentiation, 
decrease inflammation and alleviate pain by alternating the pain signals in the pain gate 
(Schmidtz, 2010).  
 
A study conducted by Nedelka (2014) showed that ESWT may be used as a non-invasive, 
soft tissue therapy as it results in pain reduction, tissue repair and an increase in joint 
function.  
 
The information presented in the above articles and in Chapter 2 explained why both groups 
had experienced significant clinical and statistical improvements over the three-week clinical 
trial duration. Both the treatment protocols used in this study were non-invasive, fairly simple 
techniques which had the ability to effectively relieve the symptoms associated with glute 
medius TPs despite the lack of statistical significance differences between the two groups.  
 
 
 
  
43 
 
CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
6.1 Conclusion 
The aim of the study was to compare the effectiveness of activator trigger point therapy 
versus shockwave therapy in the treatment of glute medius trigger points. 
 
In the study two groups of 15 participants were treated with group 1 receiving activator trigger 
point therapy to the glute medius TP which had been identified and group 2 receiving 
shockwave therapy to the glute medius TP which had been identified. A total of six 
treatments was administered to each participant with the seventh and final visit being for the 
purposes of data collection consultation only. 
 
Subjective data analysis in the form of the NPRS and the MPQ indicated, on average, that 
the participants in both groups had experienced a reduction in pain levels as measured by 
the subjective data. However, it was the shockwave therapy group that showed the greater 
improvement as was evident in the descriptive data which was collected over the time period. 
 
The objective data analysis involved using the pain pressure algometer that measured the 
participant’s pain threshold at a particular moment in time. Both groups showed an 
improvement in pain threshold over the course of the trial. However, there was no significant 
difference between the two groups and thus, statistically, it could not be said that either of 
the treatment interventions were more effective in treating the glute medius TP with regard 
to the pain pressure threshold. 
 
In conclusion, this suggested that neither of the treatment protocol was more effective in the 
treatment of glute medius trigger points than the other. Both modalities decreased the 
symptoms associated with the glute medius trigger points and improved the patients’ well-
being. It is for this reason that it may be said that this study has provided two different and 
effective treatment modalities for chiropractic doctors to use in the treatment of glute medius 
trigger points and the associated symptoms. 
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6.2 Recommendations 
The following recommendations are made for future research into myofascial trigger points, 
activator trigger point therapy and shockwave therapy: 
• A larger sample size per group may provide a more precise representation of the 
population. 
• A gender specific trial could be conducted in order to rule out any gender 
differences as males and females may have different presentations of symptoms 
as well as different perceptions of pain. 
• Future studies may be conducted on specific population groups, for example 
geriatrics, physically disabled individuals and athletes, in order to collect 
information on the efficacy of both activator trigger point therapy and shockwave 
therapy on a broader spectrum. 
• In order to compare the long-term effects of the treatments, a one-month follow-
up visit may be included as this would provide information in respect of 
maintenance treatment. 
• The inclusion criteria may be amended to the effect that no participant should 
participate in any physical activity during the course of the trials as the statistical 
outcome may be affected due to the fact that TPs form as a result of overuse.  
• Chiropractic manipulation combined with activator trigger point therapy or 
shockwave therapy may be included as an alternative treatment method in a third 
group. This addition will allow the study in question to take into account the 
neurological effects of manipulation on muscles and may, therefore, improve the 
outcome of the study. 
• A comparative study could be conducted using the various forms of shockwave 
therapy, namely, radial shockwave and/or focused shockwave. 
• Treatment of the entire glute medius muscle instead of treating one trigger point 
only. 
• Future studies may include the effect of each treatment protocol on muscle 
strength. 
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APPENDIX A: DR. C. NONKWELO – ADVERTISING ON CAMPUS 
PERMISSION FORM 
 
 
Dear Dr. C. Nonkwelo, 
 
My name is Susan Elizabeth Benadie, I am currently completing my Master’s degree in 
Chiropractic. I am a final year student in the process of completing my dissertation, which is 
a requirement of my degree. In order to do this, I need to conduct a research study which 
will involve the participation of students at the University of Johannesburg, Doornfontein 
Campus.  
 
My research topic is Activator Trigger Point Therapy versus Shockwave Therapy in the 
Treatment of Glute medius Trigger Points. 
 
I wish to request your permission to undertake research at the University of Johannesburg 
Doornfontein Campus and for students to participate in my research study. 
 
Kind regards 
Susan Elizabeth Benadie 
Master’s Student 
071 861 7383 
  
 
 
APPENDIX B: ADVERTISEMENT 
 
RESEARCH STUDY 
Do you suffer from lower back pain and/or 
buttock pain? 
 Activator trigger point therapy versus shockwave therapy in the 
treatment of Glute medius trigger points. 
Are you between the ages of 18 and 50 years?  
You are invited to partake in a research study aimed at treating lower back 
and /or buttock pain due to Glute medius trigger points. 
 
If you are interested, please visit me at the University of Johannesburg 
Chiropractic Day Clinic, Doornfontein Campus: Gate 7, Sherwell Road, 
Doornfontein. 
For more information do not hesitate to contact me: 
Susan Elizabeth Benadie 071 861 7383. 
Participant Initials: __________   
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APPENDIX C: INFORMATION LETTER 
 
 
DEPARTMENT OF CHIROPRACTIC 
RESEARCH STUDY INFORMATION LETTER 
REC 11.0 
 
Date: _______________________ 
 
Good Day 
 
My name is Susan Elizabeth Benadie. I WOULD LIKE TO INVITE YOU TO PARTICIPATE 
in a research study on activator trigger point therapy versus shockwave therapy in the 
treatment of glute medius trigger points. 
 
Before you decide whether or not to participate, I would like to explain to you why the 
research is being conducted and what the study will involve for you as a participant. I will 
go through the information letter with you and answer any questions you may have. 
This should take approximately 10 to 20 minutes. The study is part of a research project 
which I am undertaking as a requirement for a Master’s Degree in Chiropractic through the 
University of Johannesburg. 
 
THE PURPOSE OF THIS STUDY is to compare activator trigger point therapy versus 
shockwave therapy in the treatment of glute medius trigger points and in turn to ascertain 
the effect of the treatment of glute medius trigger points on non-specific, lower back pain. 
 
Participant Initials: __________   
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Below please find a set of questions and answers that I believe will assist you in 
understanding the relevant details of your participation in this research study. Please read 
them. If you have any further questions, I will be happy to answer them for you. 
 
1. DO I HAVE TO TAKE PART? No, you do not have to take part. It is up to you to decide 
whether or not to participate in the study. I will describe the study and go through the 
information sheet. If you agree to take part, I will then ask you to sign a consent form.  
2. WHAT EXACTLY WILL I BE EXPECTED TO DO IF I AGREE TO PARTICIPATE? On 
agreeing to participate you will be assessed for the appropriate inclusion and exclusion 
criteria. Participants will be randomly assigned into two groups of 15 participants each 
by drawing a number allocated to either group 1 or group 2 from a container. Group 1 
will receive shockwave therapy to the identified glute medius trigger point and group 2 
will receive activator trigger point therapy to the identified glute medius trigger point. You 
will receive two treatments per week over a three-week period. Subjective data collection 
includes the Numerical pain rating scale and Mc Gill’s pain questionnaire which will be 
filled in on the first, fourth and seventh consultation. Objective data collection will include 
the pressure Algometer readings which will be taken on the first, fourth and seventh 
consultations. I would like to inform you that you may not participate in any other 
research study or take any pain-killers or anti-inflammatories that may alter the results 
of this study. 
 
3. WHAT IF NEW INFORMATION BECOMES AVAILABLE? New information may 
sometimes become available about the treatment you will be receiving. If this is the case, 
I will inform you about it and discuss it with you. You may then decide whether you would 
like to continue to participate in the research study. There will be no consequences if 
you decide not to continue. However, if you do decide to continue, I will ask you to sign 
an updated consent form. 
 
4. APPROXIMATELY HOW LONG WILL MY PARTICIPATION TAKE? Your participation 
will take approximately three weeks with two treatments per week and a total of seven 
consultations. 
Participant Initials: __________   
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5. WHAT WILL HAPPEN IF I WANT TO WITHDRAW FROM THE STUDY? If you decide 
to participate in the study, you are free to withdraw your consent at any time without 
providing a reason for your decision and with no consequences. If you wish to withdraw 
your consent, you should inform me as soon as possible. 
 
6. ARE THERE ANY OTHER POSSIBLE REASONS WHY MY PARTICIPATION MIGHT BE 
TERMINATED? It may happen that, due to your health, other treatments that you may 
receive or for safety reasons, I will need to terminate your participation in this research. 
However, I will discuss this with you beforehand should this become necessary. 
 
7. IF I CHOOSE TO PARTICIPATE, WILL THERE BE ANY EXPENSES FOR ME OR 
ANY PAYMENT DUE TO ME? You will not be paid to participate in the study and you 
will not incur any expenses.  
 
8. IF I CHOOSE TO PARTICIPATE, WHAT ARE THE RISKS INVOLVED? The treatment 
interventions are aimed at relieving myofascial trigger points formed in the glute medius 
muscle and in turn associated lower back pain due to referred pain from these trigger 
points. Following the treatments, you might experience moderate pain and stiffness and 
some bruising when receiving shockwave therapy. This is a normal response and will 
be temporary. After the study is complete, I will provide you with feedback regarding the 
outcome if you wish so. 
 
9. IF I CHOOSE TO PARTICIPATE, WHAT ARE THE BENEFITS INVOLVED? Possible 
benefits of the study include relief of lower back pain due to glute medius trigger points 
and improvement of range of motion which could lead to an increase in performance 
and daily activities 
 
10. WILL MY PARTICIPATION IN THIS STUDY BE KEPT CONFIDENTIAL? All 
reasonable efforts will be made to keep your personal information confidential and to 
ensure that your right to privacy is respected. This will include substituting your 
Participant Initials: __________   
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identifying personal information with a number that only I and my research supervisor 
will know. You will not be identified in any research reports published. Under some 
circumstances, such as when required to do so by a court of law, I may have to disclose 
your personal information. In addition, it may happen that your information will need to 
be reviewed by another organisation for quality assurance purposes. However, I will 
inform about this if it happens. Although this study is not anonymous the information 
pertaining to the participants remain anonymous. 
 
11. WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY? The results 
will be included in a research report that will be assessed. In some cases, the results 
may also be published in a scientific journal. In either case, you will not be identifiable in 
any documents, reports or publications. You will also be given access to the results of 
the study if you so choose and you contact me to inform you of this. If you decide to seek 
effective treatment post-trial, you will be offered the opportunity to do so. 
 
12. WHAT WILL YOUR RESPONSIBILITIES AS THE RESEARCHER BE? As the 
researcher I am responsible for ensuring that the participants understand what will be 
expected from them, that they sign the information and consent forms and that the 
results are taken on the given times. I will also deliver the treatment to be administered 
to the best of my ability and I will show appreciation to the participants for their 
willingness to take part in the study.  
 
13. WHO IS ORGANISING AND FUNDING THIS RESEARCH STUDY?  I am organising 
the study under the guidance of my research supervisor at the Department of 
Chiropractic at the University of Johannesburg. This study has not received any funding. 
 
14. WHO HAS REVIEWED AND APPROVED THIS STUDY? Before I was allowed to 
commence the study it was reviewed in order to protect your interests. This review was 
conducted first by the Department of Chiropractic, and then by the Faculty of Health 
Sciences Research Ethics Committee at the University of Johannesburg. In both cases, 
the study was approved. 
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15. WHAT HAPPENS IF I AM INJURED DURING THE STUDY? This research is not 
covered by the institutional insurance.  In the event of an injury, you would be referred 
to the necessary medical professional although this would be at your own cost. 
 
16. ARE THERE ANY CONFLICT OF INTERESTS PERTAINING TO THIS STUDY? There 
is no conflict of interests in respect of anyone involved in the study. 
 
17. WHAT IF THERE IS A PROBLEM? If you have any concerns or complaints about this 
research study, its procedures and/or risks and benefits, you should speak to me. You 
are free to contact me at any time if you have any concerns about your participation in 
study. My contact details are as follows:  
 
Susan Elizabeth Benadie 
071 861 7383  
lanibackhouse@gmail.com 
 
You may also contact my research supervisor: 
Dr. M. Moodley 
mmoodley@uj.ac.za 
 
If you feel that any questions or complaints regarding your participation in this study have 
not been dealt with adequately, you may contact the Chairperson of the Faculty of Health 
Sciences Research Ethics Committee at the University of Johannesburg: 
 
Prof. Christopher Stein 
Tel: 011 559-6564 
Email: cstein@uj.ac.za  
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FURTHER INFORMATION AND CONTACT DETAILS: Should you require more specific 
information about this research project information or if you have any questions, concerns 
or complaints about the study, its procedures, risks and benefits, you should communicate 
with me using any of the contact details given above. 
 
 
 
Researcher: 
 
Susan Elizabeth Benadie 
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Author: Prof. C. Stein 
 
 
 
 
APPENDIX D: CONSENT FORM 
 
DEPARTMENT OF CHIROPRACTIC 
RESEARCH CONSENT FORM 
REC 11.0 
Activator Trigger Point Therapy versus Shockwave Therapy in the Treatment of Glute 
Medius Trigger Points. 
Please initial each box below: 
 
 
       I confirm that I have read and understand the information letter dated 
_______________ for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
                    I understand that my participation is voluntary and that I am free to withdraw 
from this study at any time without giving any reason and without any consequences to me. 
 
 
      I agree to participate in the above research. 
 
_______________________   ___________________________________      __________ 
      Name of Participant                Signature of Participant               Date 
 
_______________________   ___________________________________      __________ 
      Name of Researcher           Signature of Researcher               Date
 
 
 
 
 
APPENDIX E: CONTRAINDICATIONS TO RADIAL SHOCKWAVE 
THERAPY 
 
(Gerdesmeyer & Weil, 2007) 
 
Absolute contraindications: 
• Pacemaker 
• Tumour 
• Infections  
• Pregnancy 
• Application to growth joints 
• Lung tissue in direction of sound wave 
• Anti-coagulant therapies 
• Circulatory disorder 
• Disturbance of coagulation 
• Local neurological disorders 
 
 
[Type here] 
 
APPENDIX F: DIAGNOSTIC CRITERIA FOR GLUTE MEDIUS 
TRIGGER POINTS 
(Njoo & Van der Does, 1994) 
 
• Localised tenderness. 
• Referred pain (Pain over the lower back, posterior iliac crest to the sacrum, posterior 
and lateral aspect of buttock(s) and may extend into upper posterior thigh (Travell & 
Simons 2019). 
• A taut palpable band in the muscle. 
• Limited stretch range for the muscle. 
• On needling a ‘twitch’ response. 
  
[Type here] 
 
APPENDIX G: FULL CASE HISTORY 
 
 
 CASE HISTORY  
Date:    _______________________________   
Patient: _______________________________   File No. : _____________________ 
Occupation
:  
_______________________________
_  
  Age:  __________ Sex: _________   
Student:   _______________________________   Signature:____________________ 
 
FOR CLINICIAN USE ONLY:  
Initial visit clinician: _______________________    Signature: ____________________  
Case History: ____________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________      
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________
________________________________________________________________________  
Examination:         
 Previous:    UJ         Current:   UJ  
 Other Other 
X-ray Studies:                
 Previous:   UJ         Current:    UJ  
  Other Other  
Clinical Path. Lab:              
 Previous:    UJ         Current:    UJ  
  Other Other  
Case status:     
 PTT:     Conditional:     Signed off:     Final sign out:  
Recommendations: 
  
  UNIVERSITY OF JOHANNESBURG 
CHIROPRACTIC DAY CLINIC 
  
[Type here] 
 
Students case history:  
  
1. Source of History: _________________________________________  
  
2. Chief Complaint in patients own words:  
 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
________________________________________________________________________ 
  
  
 
  
  
5.  ANY OTHER COMPLAINTS  
  
________________________________________________________________________ 
  
________________________________________________________________________  
[Type here] 
 
 
[Type here] 
 
 
  
[Type here] 
 
APPENDIX H: PHYSICAL EXMINATION 
 
 
   CHIROPRACTIC DAY CLINIC 
          PHYSICAL EXAMINATION  
Underline abnormal findings in RED       Date:         _______________________  
Patient:   _________________________    File No:     _______________________  
Clinician:_________________________    Signature:_______________________  
Student:  _________________________    Signature: ______________________  
_______________________________________________________________________________ 
 
  
  
UNIVERSITY OF JOHANNESBURG   
[Type here] 
 
 
[Type here] 
 
 
[Type here] 
 
 
 
[Type here] 
[Type here] 
APPENDIX I: LUMBAR REGIONAL EXAM
   CHIROPRACTIC DAY CLINIC 
      LUMBAR REGIONAL 
  Date:         _______________________ 
Patient:   _________________________   File No:     _______________________ 
Clinician:_________________________    Signature:_______________________  
Student:  _________________________   Signature: ______________________  
UNIVERSITY OF JOHANNESBURG   
[Type here] 
[Type here] 
[Type here] 
APPENDIX J: SOAP NOTE
UNIVERSITY OF JOHANNESBURG 
CHIROPRACTIC DAY CLINIC 
SOAP NOTE 
Patient: Visit Number:  
File Number: Student: 
Date: Clinician: 
S: O:  
A: Differential Diagnosis / ICD-10 Code P: Procedure Codes 
Home Advice: Comments: 
[Type here] 
APPENDIX K: McGILL PAIN QUESTIONNAIRE FORM 
(Maire, 2002) 
Participant Number: ____________________________ Date: ____________________ 
Please read through the description below describing the different pain sensations as 
well as the severity. Tick the appropriate description/s and severity that you 
experience. 
TYPE OF PAIN 
EXPERIENCED 
NONE MILD MODERATE SEVERE 
Throbbing 0 1 2 3 
Shooting 0 1 2 3 
Stabbing 0 1 2 3 
Sharp 0 1 2 3 
Cramping 0 1 2 3 
Gnawing 0 1 2 3 
Hot-Burning 0 1 2 3 
Aching 0 1 2 3 
Heavy 0 1 2 3 
Tender 0 1 2 3 
Splitting 0 1 2 3 
Exhausting 0 1 2 3 
Sickening 0 1 2 3 
Fearful 0 1 2 3 
Punishing- Cruel 0 1 2 3 
[Type here] 
APPENDIX L: NUMERICAL PAIN RATING SCALE 
(Yeomans, 2000) 
Participant number: _________________________ 
Date: _______________________________ 
Place a mark on the pain scale below that represents your pain at this point in time. On a 
scale of 0 to 10, 0 means “no pain” and 10 means “worst possible pain”. The middle of the 
scale describes “moderate pain”. A two or three rating would be “mild pain” and a rating of 
seven or higher would indicate “severe pain”. 
Visit 1: 
No pain Moderate pain Severe pain  
0 1 2 3 4 5 6 7 8 9 10 
Visit 4: 
No pain Moderate pain Severe pain  
0 1 2 3 4 5 6 7 8 9 10 
Visit 7: 
No pain Moderate pain Severe pain  
0 1 2 3 4 5 6 7 8 9 10 
[Type here] 
APPENDIX M: PRESSURE ALGOMETER READINGS
Participant number: 
Date: 
GLTEUS MEDIUS MUSCLE 
First Visit Fourth Visit Seventh visit 
Reading 1 (kg/cm²) 
Reading 2 (kg/cm²) 
Reading 3 (kg/cm²) 
Average 
[Type here] 
APPENDIX N: HIGHER DEGREES COMMITTEE CLEARANCE 
LETTER
[Type here] 
APPENDIX O: RESEARCH ETHICS CLEARANCE LETTER
[Type here] 
 
APPENDIX P: TURNITIN REPORT 
 
[Type here] 
[Type here] 
 
 
APPENDIX Q: GROUP MEANS AND STANDARD DEVIATION OF 
VISIT 1 AND VISIT 7 FOR MPQ AND THE DIFFERENCES WITHIN 
THE GROUPS FOR ALL DATA THAT APPEARED TO BE 
STATISTICALLY INSIGNIFICANT 
Group 1 
Pain 
Descriptive 
Visit 1 Visit 7 Difference 
within the 
group  
(p-value) 
Statistical 
Significance Mean Stdev Mean Stdev 
Exhausting 0.33 0.72 0.00 0.00 0.097 
Not 
Significant 
Fearful 0.00 0.00 0.00 0.00 No Value No Value 
Heavy 0.33 0.90 0.07 0.25 0.135 
Not 
Significant 
Hot and 
Burning 0.07 0.25 0.00 0.00 0.368 
Not 
Significant 
Punishing - 
Cruel 0.07 0.25 0.00 0.00 0.368 
Not 
Significant 
Sickening 0.13 0.51 0.00 0.00 0.368 
Not 
Significant 
Splitting 0.00 0.00 0.00 0.00 No Value No Value 
Stabbing 0.20 0.56 0.00 0.00 0.368 
Not 
Significant 
 
 
Group 2 
Pain 
Descriptive 
Visit 1 Visit 7 Difference 
within the 
group   
(p-value) 
Statistical 
Significance Mean Stdev Mean Stdev 
Exhausting 0.33 0.81 0.01 0.25 0.273 
Not 
Significant 
Fearful 0.00 0.00 0.00 0.00 No Value No Value 
Heavy 0.33 0.90 0.27 0.79 0.867 
Not 
Significant 
Hot and 
Burning 0.27 0.79 0.00 0.00 0.156 
Not 
Significant 
Punishing - 
Cruel 0.00 0.00 0.00 0.00 No Value No Value 
Sickening 0.07 0.25 0.07 0.25 No Value No Value 
Splitting 0.00 0.00 0.00 0.00 No Value No Value 
Stabbing 0.20 0.77 0.00 0.00 0.368 
Not 
Significant 
 
